These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2016 related articles for article (PubMed ID: 17578167)

  • 1. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin inhibition in hypertension.
    Gradman AH; Kad R
    J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S; Choy M
    Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a future for direct renin inhibitors?
    Chaudhary K; Nistala R; Whaley-Connell A
    Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advantages and limitations of renin inhibition with aliskiren].
    Azizi M; Frank M; Steichen O; Blanchard A
    Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?
    Gaddam KK; Oparil S
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.